Taurus Vascular
Developing a minimally invasive catheter and implantable shunt to treat endoleaks after EVAR.
Website: https://mtec-sc.org/life-sciences/taurus-vascular
Cover Block
From the public record
| Field | Detail |
|---|---|
| Company | Taurus Vascular |
| Tagline | Developing a minimally invasive catheter and implantable shunt to treat endoleaks after EVAR. [Rice Alliance, accessed 2026] |
| Headquarters | Houston, United States [LinkedIn] |
| Founded | 2022 [Crunchbase] |
| Stage | Seed [LinkedIn, June 2024] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2): Matthew Kuhn and Melanie Lowther [InnovationMap, July 2023] |
| Funding label | Seed |
| Total disclosed funding | Approximately $1.3 million [LinkedIn, June 2024] |
Links
From the public record
The Short Version
PUBLIC Taurus Vascular is building a catheter-delivered implantable shunt for endoleaks after EVAR, and it merits investor attention because it is pursuing a specific post-procedure vascular complication with an early financing and recent third-party validation already on record [InnovationMap, July 2023] [LinkedIn, June 2024] [InnovationMap, July 2024]. The company emerged from the Texas Medical Center Innovation Biodesign program, where Matthew Kuhn and Melanie Lowther were identified as the fellows behind the concept, which gives the founding story a clinical problem-first origin rather than a generic device spinout narrative [InnovationMap, July 2023].
The product thesis is straightforward: Taurus is developing a minimally invasive catheter and implantable shunt intended to create a drainage pathway from a high-pressure aneurysm sac to a nearby low-pressure vein, with the goal of reducing sac pressure and improving repair durability after EVAR [Rice Alliance, accessed 2026] [InnovationMap, July 2023]. That approach appears differentiated in the public record by its focus on treating endoleaks through a catheter-delivered, self-deploying shunt architecture, although the available sources do not yet establish clinical data, regulatory progress, or commercial adoption [Rice Alliance, accessed 2026] [InnovationMap, July 2023].
On team, the public record supports Kuhn as founder and CEO and Lowther as co-founder and COO; it also shows Lowther with prior healthcare operating exposure through Endeavor Management, where company materials describe more than 20 years in healthcare innovation and 14 years in not-for-profit healthcare and payor systems [Rice Alliance, accessed 2026] [Endeavor Management, accessed 2026] [LinkedIn]. That matters because this is a medtech build that will likely depend as much on disciplined development and clinical execution as on the initial device concept.
Capital formation is still lightly documented, but Taurus announced $1.3 million in seed funding in June 2024, and it later won first place in the Texas A&M New Ventures Competition in July 2024, which InnovationMap reported carried a $30,000 prize [LinkedIn, June 2024] [InnovationMap, July 2024]. The model reads as hardware plus software in healthtech, with revenue likely to depend on eventual hospital adoption and procedure integration, though no customer deployments or signed health system relationships were verifiable in the public materials reviewed [Rice Alliance, accessed 2026] [InnovationMap, July 2023].
Over the next 12 to 18 months, the key watchpoints are whether Taurus can translate seed capital into preclinical validation milestones, verification and validation progress, and a credible path toward first-in-human work, all of which were referenced in the reporting around its development plan [InnovationMap, July 2023] [LinkedIn, June 2024]. For investors, the opportunity is interesting because the clinical use case is concrete and the company has early ecosystem support, but conviction should still turn on evidence that the device can move from concept and competition visibility into reproducible clinical and regulatory execution [InnovationMap, July 2024] [Rice Alliance, accessed 2026].
Single-source, plausible -- Based primarily on company profile materials, LinkedIn funding disclosure, and InnovationMap reporting; several core product and team claims have only partial independent corroboration.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed about $1.3 million |
The Company in Brief
PUBLIC
Taurus Vascular appears to be an early-stage Houston medtech company formed around a narrow but clinically serious problem: endoleaks that persist after endovascular aortic aneurysm repair. Public company profiles describe the business as developing a minimally invasive catheter and implantable shunt intended to treat that complication, with headquarters in Houston and a 2022 founding date [Crunchbase] [Rice Alliance, accessed 2026].
The public timeline is still short, but it is coherent. Rice Alliance describes Taurus Vascular as a company emerging from the Texas Medical Center Innovation Biodesign program, while InnovationMap reported in July 2023 that biodesign fellows Matthew Kuhn and Melanie Lowther were preparing to spin the venture out around its endoleak-focused device concept [Rice Alliance, accessed 2026] [InnovationMap, July 2023]. 3 million in seed funding; one month later, InnovationMap reported that the company won first place in the Texas A&M New Ventures Competition [Crunchbase] [LinkedIn, June 2024] [InnovationMap, July 2024]. No public state filing or legal entity detail was provided in the source set, so the entity structure cannot be confirmed here.
Single-source, plausible -- Core company identity is corroborated by Crunchbase and Rice Alliance, but milestone details in this section rely in part on a LinkedIn funding announcement and publisher coverage rather than state filings.
What They Have Built
Mixed sourcing
Taurus Vascular is working on a device for a narrow but clinically significant problem: endoleaks that occur after endovascular aortic aneurysm repair, or EVAR [InnovationMap, July 2023]. Public descriptions are consistent on the core concept. The company is developing a minimally invasive catheter and implantable shunt, described as a catheter-delivered, self-deploying stent or shunt, for patients with abdominal aortic aneurysms who develop endoleaks after EVAR [Rice Alliance] [InnovationMap, July 2023].
The technical mechanism, as publicly described, is to create a drainage pathway from the high-pressure aneurysm sac to a nearby low-pressure vein, with the aim of reducing sac pressure and improving long-term repair durability [Rice Alliance] [InnovationMap, July 2023]. That matters because the company is not presenting a general vascular platform in the available record. It is presenting a specific intervention for a defined post-EVAR complication, which makes the product story easier to diligence but leaves less room, in the public record, to assess adjacent indications or broader platform economics [Rice Alliance] [InnovationMap, July 2023].
The public development record also suggests the technology remains pre-commercial. InnovationMap reported in July 2023 that Taurus's next step was raising seed funding to support chronic animal studies, and later public materials do not identify commercial deployments, named hospital customers, or first-in-human completion [InnovationMap, July 2023] [InnovationMap, July 2024]. No verified demo materials or public technical stack disclosures surfaced in the source set, and there were no citable job postings that would support software or systems inferences. On public evidence alone, the investable question is less about feature breadth than about whether this drainage approach can translate from concept and preclinical work into a reproducible interventional workflow.
Single-source, plausible -- Product descriptions are corroborated across Rice Alliance and InnovationMap, but current stage and lack of deployment detail rely on limited public reporting.
Market Size and Demand
From the public record
This market matters because Taurus Vascular is pursuing a complication of a large, already-established aortic repair pathway, and device startups in that position can benefit from existing procedural infrastructure if they solve a persistent post-procedure failure mode [InnovationMap, July 2023].
The public record here is narrower than an institutional investor would usually want. No named third-party market report in the gathered sources provides a direct TAM, SAM, or SOM for post-EVAR endoleak treatment, so any sizing discussion has to stay qualitative rather than pretend to precision. What is documented is the clinical wedge: Taurus is developing a catheter-delivered implantable shunt for patients with abdominal aortic aneurysms who develop endoleaks after endovascular aortic aneurysm repair, or EVAR [Rice Alliance, accessed 2026; InnovationMap, July 2023]. That matters because it places the company inside the broader vascular intervention and aneurysm repair ecosystem rather than in a de novo care pathway.
Demand, if the product works as intended, is tied to the installed base of EVAR procedures and the persistence of post-repair surveillance and reintervention needs. InnovationMap's 2023 reporting describes Taurus's concept as a way to address endoleaks by creating a drainage route from the aneurysm sac to a nearby low-pressure vein, with the aim of reducing sac pressure and improving long-term repair durability [InnovationMap, July 2023]. The underlying commercial implication is straightforward but still conditional: hospitals and vascular teams already managing EVAR patients may prefer an additional minimally invasive tool over more invasive follow-on interventions, but the public materials do not yet establish clinical adoption, reimbursement, or physician purchasing behavior [Rice Alliance, accessed 2026].
The closest adjacent markets are endovascular aneurysm repair devices, peripheral vascular implants, interventional radiology tools, and post-EVAR surveillance or reintervention workflows. Taurus's product description suggests it would sit near these categories operationally, since the device is catheter delivered and intended for a specific complication after a prior endovascular repair [Rice Alliance, accessed 2026; InnovationMap, July 2023]. The main substitute, based on the available sources, is not another named startup or product but the status quo of existing endoleak management approaches, which means the company's eventual market access case will likely depend less on creating a new category and more on proving better risk-benefit or workflow fit within current vascular practice.
Regulatory and macro forces cut both ways. On the favorable side, medtech programs such as Texas Medical Center Innovation Biodesign, MassChallenge U.S., MedTech Innovator, and the Texas A&M New Ventures Competition indicate continued ecosystem support for vascular-device formation and early non-dilutive validation signals [InnovationMap, July 2024; LinkedIn, June 2024]. On the harder side, the same source set makes clear that Taurus was, as of 2024, still funding development work tied to chronic animal studies and discussing a future Series A for first-in-human studies, verification and validation testing, and continued product development, which underscores the long regulatory and clinical evidence path typical of implantable devices [InnovationMap, July 2023; LinkedIn, June 2024]. That does not weaken the clinical need, but it does mean market timing is likely to be governed by trial execution and regulatory sequencing rather than by top-of-funnel customer interest alone.
| Cited market-relevant claim | Reading for market demand | Source |
|---|---|---|
| Taurus targets patients with abdominal aortic aneurysms who develop endoleaks after EVAR | Defines the initial indication as a post-procedure complication market within aneurysm care | [Rice Alliance, accessed 2026] |
| Device is a catheter-delivered, self-deploying stent or shunt intended to reduce sac pressure | Suggests fit with minimally invasive vascular workflows rather than open surgical replacement | [InnovationMap, July 2023] |
| Seed funding was described as supporting chronic animal studies | Implies the commercial market remains preclinical and evidence-gated | [InnovationMap, July 2023; LinkedIn, June 2024] |
| Taurus won first place in the Texas A&M New Ventures Competition | Indicates early external validation, but not market adoption | [InnovationMap, July 2024] |
The table shows a market that is conceptually legible but still thinly quantified in public. Investors can underwrite the existence of a real clinical use case from the sources, but not yet a defensible market size model without outside epidemiology, procedure-volume data, and reimbursement work.
Single-source, plausible -- Section rests on named public sources that confirm the clinical use case and development stage, but no third-party market sizing report was identified in the gathered record.
Who Else Is Fighting for This
MIXED Taurus Vascular appears to be positioning itself less against a crowded field of named startup peers and more against the clinical status quo for managing endoleaks after EVAR, which makes the real competitive set broader than the cap table suggests [InnovationMap, July 2023] [Rice Alliance, accessed 2026].
The public record supports a narrow product definition but not a clean peer set. Taurus is developing a catheter-delivered implantable shunt for patients with abdominal aortic aneurysms who develop endoleaks after EVAR, with the stated mechanism of draining the aneurysm sac into a nearby low-pressure vein [PUBLIC] [InnovationMap, July 2023] [Rice Alliance, accessed 2026]. What that implies competitively is that the first line of competition is likely incumbent procedural management inside vascular surgery and interventional radiology, rather than a clearly disclosed list of venture-backed companies pursuing the same architecture. The second layer is adjacent device makers already trusted in endovascular workflows, even if the available sources do not identify direct product-level rivals by name [InnovationMap, July 2023].
That distinction matters because Taurus's current edge, on public evidence, is conceptual and clinical-workflow oriented rather than commercial. The company came out of the Texas Medical Center Innovation Biodesign program, and its public materials describe a specific post-EVAR complication with a minimally invasive intervention path [PUBLIC] [InnovationMap, July 2023] [Rice Alliance, accessed 2026]. In medtech, that can be a meaningful early advantage if the problem definition is precise and the procedure can fit existing operator behavior. It is also perishable. Until there is public evidence of clinical data, hospital adoption, regulatory progress, or channel access, the advantage rests mainly on design intent and founder proximity to the problem rather than on a moat that later entrants would struggle to replicate [InnovationMap, July 2023] [LinkedIn, June 2024].
The company is most exposed where larger endovascular incumbents tend to be strongest: physician relationships, trial infrastructure, and the ability to absorb a long evidence cycle. A strategic incumbent already selling into aortic repair would likely hold the distribution advantage if it chose to pursue a similar adjunct therapy, while Taurus would have to prove not only device performance but also procedural adoption economics from a much smaller capital base. The disclosed seed financing of $1.3 million in June 2024 is enough to signal forward motion, not category control [PUBLIC] [LinkedIn, June 2024].
The most plausible 18-month scenario is less a head-to-head startup race than a validation race between Taurus and existing standard-of-care workarounds. Taurus is the likely winner if chronic-animal and early verification work translate into a credible first-in-human path, because a targeted solution for persistent endoleaks could earn attention disproportionate to the company's size [PUBLIC] [InnovationMap, July 2023] [LinkedIn, June 2024]. Taurus is the likely loser if incumbent procedural alternatives remain good enough in practice or if a better-capitalized endovascular platform owner moves first with a comparable approach. On the evidence available, the competitive question is not whether Taurus has no competition. It is whether it can become the specialist option before generalist device companies decide the niche is worth owning.
Opportunity
PUBLIC The prize here is not a broader vascular platform yet, but a narrower and still meaningful outcome: becoming a standard adjunct device for one of the more consequential failure modes after EVAR, in a part of medtech where a single accepted procedural solution can carry outsized strategic value [InnovationMap, July 2023] [Rice Alliance, accessed 2026].
The headline opportunity is straightforward. If Taurus Vascular can show that its catheter-delivered implant reliably lowers aneurysm sac pressure in patients who develop endoleaks after EVAR, it could become a category-level solution inside a defined but clinically important post-procedure workflow [InnovationMap, July 2023] [Rice Alliance, accessed 2026]. That is reachable, rather than purely aspirational, because the company is not proposing a general-purpose platform with unclear first use. The public record points to a specific complication, a specific anatomical approach, and a device concept that emerged from Texas Medical Center Innovation Biodesign and was developed far enough to attract seed funding and competition support in 2024 [InnovationMap, July 2023] [LinkedIn, June 2024] [InnovationMap, July 2024].
That focus matters. Hospitals do not need to change an entire vascular program for Taurus to matter; they need evidence that a serious EVAR complication can be managed with a minimally invasive shunt-based approach that fits existing interventional practice patterns [InnovationMap, July 2023] [Rice Alliance, accessed 2026]. If Taurus can supply that evidence, the company could become acquisition-relevant to strategics already active in vascular devices, even before it looks like an independent commercial-scale company. Public sources do not establish that outcome, but they do establish the ingredients of the bet: a defined clinical wedge, a founder team formed through a medtech design program, and early financing to advance development [InnovationMap, July 2023] [LinkedIn, June 2024].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Standard-of-care adjunct | Taurus shows enough safety and procedural utility for its shunt to become a repeat-use adjunct for selected post-EVAR endoleak cases at vascular centers. | Strong preclinical and first-in-human data that support reduced sac pressure and acceptable deployment characteristics. | The company is building for a specific complication after EVAR, and public descriptions already frame the device as a catheter-delivered, self-deploying shunt for that use case [InnovationMap, July 2023] [Rice Alliance, accessed 2026]. |
| Strategic tuck-in | Taurus advances through early human evidence and becomes a logical add-on asset for a larger vascular-device company that already sells into EVAR and interventional teams. | Early clinical validation plus a clearer regulatory path after seed-funded development milestones. | Kuhn stated in June 2024 that Taurus had secured $1.3 million in seed funding, and public reporting indicates the company was preparing for chronic animal studies and later first-in-human work, which is often the value-inflection sequence strategics watch in device categories [LinkedIn, June 2024] [InnovationMap, July 2023]. |
| Procedure-platform expansion | Taurus proves the initial shunt concept, then extends the underlying approach into adjacent aneurysm or post-repair complications using the same delivery logic. | A successful first indication that validates the drainage mechanism and operator workflow. | The current product description centers on a mechanism, drainage from a high-pressure aneurysm sac to a nearby low-pressure vein, that is narrow enough to test in one indication but conceptually extensible if the first application works [Rice Alliance, accessed 2026] [InnovationMap, July 2023]. |
The compounding mechanism, if it appears, would likely look more like procedural credibility than a software-style network effect. One successful indication can make the second one cheaper to pursue because physician training, delivery know-how, bench testing methods, and regulatory evidence packages start to accumulate around the same device architecture [InnovationMap, July 2023]. Taurus also has some early signs of ecosystem pull, not commercial pull yet, through TMC Innovation Biodesign, a disclosed seed raise, and recognition at the Texas A&M New Ventures Competition, all of which can matter in medtech because they help recruit trial partners, technical advisors, and follow-on capital before revenue exists [InnovationMap, July 2023] [LinkedIn, June 2024] [InnovationMap, July 2024].
The size of the win is harder to pin down from public evidence because no credible market-size report or direct public comparable was provided in the source set. The more defensible upside framing is therefore strategic, not spreadsheet-heavy: if Taurus reaches the point where its device is viewed as a credible solution for a meaningful share of post-EVAR endoleak management, the company could plausibly become a tuck-in target for a larger vascular medtech platform at the first meaningful human-evidence inflection point (scenario, not a forecast) [InnovationMap, July 2023] [Rice Alliance, accessed 2026]. That is a narrower statement than claiming a standalone category leader, but it is also the more supportable public-case upside at this stage, given the company's focus, financing history, and development path as currently documented [LinkedIn, June 2024] [InnovationMap, July 2024].
Single-source, plausible -- This section relies primarily on InnovationMap reporting, Rice Alliance's company profile, and a June 2024 LinkedIn funding announcement. Public sources support the product concept and development path, but they do not yet provide independent clinical results, customer adoption, or market-size benchmarks.
Sources
From the public record
[Rice Alliance, accessed 2026] Taurus Vascular | Rice Alliance | https://alliance.rice.edu/person/taurus-vascular
[LinkedIn, June 2024] Taurus Vascular | LinkedIn | https://www.linkedin.com/company/taurus-vascular
[InnovationMap, July 2023] Houston biodesign innovators ready to spin out startup with life-saving vascular tech | https://houston.innovationmap.com/texas-medical-center-biodesign-taurus-vascular-2662229775.html
[InnovationMap, July 2024] Houston health tech startup scores $30,000 prize at annual pitch competition | https://houston.innovationmap.com/taurus-vascular-tnvc-matthew-kuhn-2668671745.html
[Endeavor Management, accessed 2026] Melanie Lowther | Endeavor Management | https://endeavormgmt.com/team-member/melanie-lowther
Articles about Taurus Vascular
- Taurus Vascular's Shunt Aims to Fix a $2 Billion EVAR Complication — The Houston startup, born from a medical biodesign program, is using a $1.3 million seed to advance its catheter-delivered device for endoleaks.